121 related articles for article (PubMed ID: 29638149)
21. A review of kinases implicated in pancreatic cancer.
Giroux V; Dagorn JC; Iovanna JL
Pancreatology; 2009; 9(6):738-54. PubMed ID: 20090395
[TBL] [Abstract][Full Text] [Related]
22. Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study.
Thamm DH; Rose B; Kow K; Humbert M; Mansfield CD; Moussy A; Hermine O; Dubreuil P
Vet J; 2012 Jan; 191(1):131-4. PubMed ID: 21333567
[TBL] [Abstract][Full Text] [Related]
23. Clinical response of masitinib mesylate in the treatment of canine macroscopic mast cell tumours.
Grant J; North S; Lanore D
J Small Anim Pract; 2016 Jun; 57(6):283-90. PubMed ID: 27136424
[TBL] [Abstract][Full Text] [Related]
24. Targeting protein kinase C subtypes in pancreatic cancer.
Storz P
Expert Rev Anticancer Ther; 2015 Apr; 15(4):433-8. PubMed ID: 25604078
[TBL] [Abstract][Full Text] [Related]
25. Safety of masitinib mesylate in healthy cats.
Daly M; Sheppard S; Cohen N; Nabity M; Moussy A; Hermine O; Wilson H
J Vet Intern Med; 2011; 25(2):297-302. PubMed ID: 21314730
[TBL] [Abstract][Full Text] [Related]
26. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
Gomes EG; Connelly SF; Summy JM
Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
[TBL] [Abstract][Full Text] [Related]
27. New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies.
Matera R; Saif MW
Expert Opin Emerg Drugs; 2017 Sep; 22(3):223-233. PubMed ID: 28783977
[TBL] [Abstract][Full Text] [Related]
28. Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial.
Cadot P; Hensel P; Bensignor E; Hadjaje C; Marignac G; Beco L; Fontaine J; Jamet JF; Georgescu G; Campbell K; Cannon A; Osborn SC; Messinger L; Gogny-Goubert M; Dubreuil P; Moussy A; Hermine O
Vet Dermatol; 2011 Dec; 22(6):554-64. PubMed ID: 21668810
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
Le Cesne A; Blay JY; Bui BN; Bouché O; Adenis A; Domont J; Cioffi A; Ray-Coquard I; Lassau N; Bonvalot S; Moussy A; Kinet JP; Hermine O
Eur J Cancer; 2010 May; 46(8):1344-51. PubMed ID: 20211560
[TBL] [Abstract][Full Text] [Related]
30. Masitinib is safe and effective for the treatment of canine mast cell tumors.
Hahn KA; Ogilvie G; Rusk T; Devauchelle P; Leblanc A; Legendre A; Powers B; Leventhal PS; Kinet JP; Palmerini F; Dubreuil P; Moussy A; Hermine O
J Vet Intern Med; 2008; 22(6):1301-9. PubMed ID: 18823406
[TBL] [Abstract][Full Text] [Related]
31. Brief overview of selected approaches in targeting pancreatic adenocarcinoma.
Samore WR; Gondi CS
Expert Opin Investig Drugs; 2014 Jun; 23(6):793-807. PubMed ID: 24673265
[TBL] [Abstract][Full Text] [Related]
32. Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein.
Zandvliet M; Teske E; Chapuis T; Fink-Gremmels J; Schrickx JA
J Vet Pharmacol Ther; 2013 Dec; 36(6):583-7. PubMed ID: 23363222
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.
Pishvaian MJ; Brody JR
Oncology (Williston Park); 2017 Mar; 31(3):159-66, 168. PubMed ID: 28299752
[TBL] [Abstract][Full Text] [Related]
34. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials.
Mosquera C; Maglic D; Zervos EE
Cancer Genet; 2016 Dec; 209(12):567-581. PubMed ID: 27613577
[TBL] [Abstract][Full Text] [Related]
35. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
37. FAK and paxillin, two potential targets in pancreatic cancer.
Kanteti R; Batra SK; Lennon FE; Salgia R
Oncotarget; 2016 May; 7(21):31586-601. PubMed ID: 26980710
[TBL] [Abstract][Full Text] [Related]
38. Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer.
Welch SA; Moore MJ
Future Oncol; 2007 Jun; 3(3):247-54. PubMed ID: 17547518
[TBL] [Abstract][Full Text] [Related]
39. Piroxicam inhibits Masitinib-induced cyclooxygenase 2 expression in oral squamous cell carcinoma cells in vitro.
Rathore K; Alexander M; Cekanova M
Transl Res; 2014 Aug; 164(2):158-68. PubMed ID: 24631063
[TBL] [Abstract][Full Text] [Related]
40. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
Al Haddad AH; Adrian TE
Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
